Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone implant plus CBT for amphetamine addiction
ACTRN12618000568213Phase 2Suspended
- Sponsor
- Go Medical Industries
- Start
- Apr 2019
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of OLANI in amphetamine-type use disorder and amphetamine dependence (2 arms), sponsored by Go Medical Industries. Primary endpoints: Number of positive weekly amphetamine/ICE urine drug screens at 24 weeks, Time to return to problematic amphetamine/ICE use and 1 more. Started Apr 2019; status: suspended.
02
Drugs
OLANI
03
Conditions
amphetamine-type use disorderamphetamine dependence
Beyond the preview
Go deeper on ACTRN12618000568213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000568213.